EXPLANATORY STATEMENT
Subject: MANUFACTURING PRINCIPLES - MP 1/2002
(S.36(1) Therapeutic Goods Act 1989)
The Therapeutic Goods Act 1989 (the Act), which came into effect on 15 February 1991, regulates the establishment and maintenance of a national system of controls relating to the quality, safety and efficacy of therapeutic goods for use in humans.
Section 36 of the Act empowers the Minister to determine, as required, principles to be observed by manufacturers of therapeutic goods relating, inter alia, to standards to be maintained, the procedures to be adopted and the manufacturing practices to be employed in the manufacture of such goods.
Having consulted with the Therapeutic Goods Committee established under the Therapeutic Goods Regulations to, amongst other things, consider principles to be observed in the manufacture of therapeutic goods for human use and to advise the Minister accordingly, the Parliamentary Secretary to the Minister has determined that the Manufacturing Principles specified in MP 1/2002 (attached) will apply to the manufacture of active pharmaceutical ingredients. The purpose of the Manufacturing Principles is to establish the minimum requirements to be observed for the manufacture of active pharmaceutical ingredients for use in the manufacture of medicines for human use.
This Determination adopts the ICH (International Conference on Harmonisation) Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients as a Manufacturing Principle for the audit and licensing of manufacturers of active pharmaceutical ingredients in Australia. The adoption of this document as a Manufacturing Practice will ensure that Australia’s manufacturing requirements for active pharmaceutical ingredients are harmonised with other countries such as USA, Europe, Switzerland, Japan and Singapore. Australian manufacturers of active pharmaceutical ingredients will benefit through increased export opportunities to export their products to many more countries than previously.
The application of the ICH GMP Guide to overseas manufacturers of active pharmaceutical ingredients used in therapeutic goods supplied to Australia will continue to apply only to prescription medicines evaluated by the Drug Safety and Evaluation Branch of TGA.
A 12-month transition period will apply from the time the Guide is gazetted as a Manufacturing Principle.
The Manufacturing Principles MP1/2002 commenced operating on the date of gazettal, which was 29 May 2002 (Gazette No. GN 21).
Overview
The Therapeutic Goods Act 1989 was enacted to establish a comprehensive regulatory framework governing the quality, safety, and efficacy of therapeutic goods intended for human use. The Act came into effect on 15 February 1991, with Section 36 specifically empowering the Minister to set manufacturing principles for therapeutic goods, including standards and practices to be adhered to in their production. In 2002, the Minister, after consulting with the Therapeutic Goods Committee, determined that the Manufacturing Principles specified in MP 1/2002 would apply to the manufacture of active pharmaceutical ingredients. This decision was formalised through a legislative instrument gazetted on 29 May 2002, which aimed to establish minimum requirements for manufacturing active pharmaceutical ingredients in alignment with international standards, thereby facilitating increased export opportunities for Australian manufacturers. The policy objective behind these principles was to harmonise Australia's manufacturing requirements with those of other major global markets, ensuring that Australian therapeutic goods meet internationally recognised standards.
Scope and Application
The Manufacturing Principles specified in MP 1/2002 apply to the manufacture of active pharmaceutical ingredients and are intended to establish minimum requirements for their production to ensure the quality, safety, and efficacy of medicines intended for human use. This determination, made under the Therapeutic Goods Act 1989, mandates that Australian manufacturers of active pharmaceutical ingredients observe these principles, which are based on the ICH Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. This ensures that Australia’s manufacturing standards are harmonised with those of other major jurisdictions, facilitating increased export opportunities for Australian manufacturers. Additionally, the principles will apply to overseas manufacturers whose products are supplied to Australia, specifically for prescription medicines evaluated by the Therapeutic Goods Administration. The adoption of these principles commenced on 29 May 2002, with a 12-month transition period for compliance.
Key Provisions
The key operative sections of MP 1/2002 include those that specify the minimum requirements for the manufacture of active pharmaceutical ingredients (API) for human use. This document, which adopts the ICH GMP Guide, outlines the standards, procedures, and practices that must be observed by manufacturers. Section 36(1) of the Therapeutic Goods Act 1989 empowers the Minister to determine these principles, and MP 1/2002 details the specific requirements under this mandate. These provisions ensure that the manufacture of APIs adheres to internationally recognised standards, enhancing the quality, safety, and efficacy of therapeutic goods.
Manufacturers of active pharmaceutical ingredients in Australia must comply with the principles set out in MP 1/2002. This includes adhering to the ICH GMP Guide, which encompasses various aspects such as quality management, personnel qualifications, facility and equipment standards, documentation practices, and production processes. By complying with these principles, manufacturers ensure that their products meet the necessary regulatory standards and can be safely used in the production of therapeutic goods for human use. The obligations extend to maintaining appropriate records and documentation, ensuring that facilities and equipment are regularly inspected and maintained, and implementing effective quality control systems.
Breach of the manufacturing principles set out in MP 1/2002 can lead to significant consequences. Under the Therapeutic Goods Act 1989, non-compliance with manufacturing standards can result in penalties, including fines and potential criminal charges for serious offences. The Act also provides for the suspension or cancellation of manufacturing authorisations, which can severely impact a manufacturer's ability to operate. Additionally, any therapeutic goods produced under non-compliant conditions may be subject to recall, further impacting the manufacturer's reputation and market access. The maximum penalties for breaches can vary depending on the severity of the offence but are intended to enforce stringent adherence to the prescribed manufacturing principles.
MP 1/2002 and its alignment with the ICH GMP Guide also have implications for overseas manufacturers supplying APIs to Australia. While the principles apply primarily to Australian manufacturers, overseas suppliers must also ensure their products meet these standards to be accepted in the Australian market. The Therapeutic Goods Administration (TGA) continues to evaluate the compliance of imported APIs, and non-compliance can result in the refusal of entry for the goods, legal action, or other regulatory measures. This dual application of the principles ensures that both domestic and imported therapeutic goods meet the required safety and quality standards, protecting public health.